A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Public ClinicalTrials.gov record NCT06941272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Study identification
- NCT ID
- NCT06941272
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- Patritumab Deruxtecan Biological
Biological
Eligibility (public fields only)
- Age range
- 1 Month to 17 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2025
- Primary completion
- Dec 29, 2030
- Completion
- Dec 29, 2030
- Last update posted
- Apr 12, 2026
2025 – 2030
United States locations
- U.S. sites
- 17
- U.S. states
- 16
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital Los Angeles ( Site 3006) | Los Angeles | California | 90027 | Recruiting |
| Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 3016) | Aurora | Colorado | 80045 | Recruiting |
| Yale New Haven Hospital ( Site 3012) | New Haven | Connecticut | 06510 | Recruiting |
| Johns Hopkins All Children's Hospital ( Site 3025) | St. Petersburg | Florida | 33701 | Recruiting |
| University of Iowa Health Care Holden Comprehensive Cancer Center ( Site 3017) | Iowa City | Iowa | 52242 | Recruiting |
| Dana-Farber Cancer Institute ( Site 3013) | Boston | Massachusetts | 02215 | Recruiting |
| Corewell Health ( Site 3001) | Grand Rapids | Michigan | 49503 | Recruiting |
| Children's Mercy Hospital ( Site 3024) | Kansas City | Missouri | 64108 | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 3008) | New Brunswick | New Jersey | 08901 | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 3010) | New York | New York | 10065 | Recruiting |
| New York Medical College ( Site 3023) | Valhalla | New York | 10595 | Recruiting |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3003) | Fargo | North Dakota | 58102 | Recruiting |
| Oregon Health and Science University ( Site 3004) | Portland | Oregon | 97239 | Recruiting |
| Children's Hospital of Philadelphia (CHOP) ( Site 3021) | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Sanford Children's Hospital ( Site 3015) | Sioux Falls | South Dakota | 57117 | Recruiting |
| University of Texas-MD Anderson Cancer Center ( Site 3007) | Houston | Texas | 77030 | Recruiting |
| Intermountain - Primary Children's Hospital ( Site 3014) | Salt Lake City | Utah | 84113 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06941272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06941272 live on ClinicalTrials.gov.